These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9629750)

  • 1. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
    Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
    Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
    Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
    AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
    Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
    Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)].
    Acevedo W; Gallardo AM; Galaz J; Afani A; Cortés E
    Rev Med Chil; 2007 Nov; 135(11):1406-13. PubMed ID: 18259651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.
    Holguín A; Dietrich U; Immelmann A; Soriano V
    Antivir Ther; 1998; 3(3):183-6. PubMed ID: 10682136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
    Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
    Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
    Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human immunodeficiency virus and resistance].
    Coórdoba J; Otero MC; Laínez B; Pérez-Tamarit D; Molina JM; Calvo MA; Asensi F; Gobernado M
    Rev Esp Quimioter; 1998 Jun; 11(2):152-6. PubMed ID: 9795301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
    Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
    J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
    Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
    J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of mutations that confer resistance to nucleoside analogs and protease inhibitors in HIV-1-infected patients. Study Group on Resistance to Antiretroviral Agents].
    Martínez G; Sarría L; Campelo C; Merchán A; Cisterna R
    Rev Esp Quimioter; 1999 Dec; 12(4):317-24. PubMed ID: 10855010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
    Shepp DH; Ashraf A; Tang IT; Match ME; Millan C; Pergolizzi R
    J Med Virol; 1996 Aug; 49(4):303-10. PubMed ID: 8877763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.